Report - LAIDLAW & COMPANY · 4/12/2018  · • ME-401, a distinct oral PI3K delta inhibitor, could enter a pivotal study in follicular lymphoma (FL) in late 2H18 after reporting the Phase

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form